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Abstract: We have previously identified substantial antibiotic treatment heterogeneity, even among
organism-specific and site-specific infections with treatment guidelines. Therefore, we sought to
quantify the extent of treatment heterogeneity among patients hospitalized with P. aeruginosa pneumonia in the national Veterans Affairs Healthcare System from Jan-2015 to Apr-2018. Daily antibiotic exposures were mapped from three days prior to culture collection until discharge. Heterogeneity was defined as unique patterns of antibiotic treatment (drug and duration) not shared by any
other patient. Our study included 5300 patients, of whom 87.5% had unique patterns of antibiotic
drug and duration. Among patients receiving any initial antibiotic/s with a change to at least one
anti-pseudomonal antibiotic (n = 3530, 66.6%) heterogeneity was 97.2%, while heterogeneity was
91.5% in those changing from any initial antibiotic/s to only anti-pseudomonal antibiotics (n = 576,
10.9%). When assessing heterogeneity of anti-pseudomonal antibiotic classes, irrespective of other
antibiotic/s received (n = 4542, 85.7%), 50.5% had unique patterns of antibiotic class and duration,
with median time to first change of three days, and a median of two changes. Real-world evidence
is needed to inform the development of treatment pathways and antibiotic stewardship initiatives
based on clinical outcome data, which is currently lacking in the presence of such treatment heterogeneity.
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1. Introduction
Pseudomonas aeruginosa is an important nosocomial pathogen, often causing pneumonia in hospitalized patients [1,2]. Second only to Staphylococcus aureus, P. aeruginosa is the
most common Gram-negative pathogen isolated from hospitalized patients with bacterial
pneumonia [3]. P. aeruginosa is the fourth most common cause of nosocomial infections,
and the leading Gram-negative cause of both hospital-acquired (HABP) and ventilatoracquired bacterial pneumonia (VABP) in the United States (US) and an important nosocomial pathogen worldwide [3–7]. Further, P. aeruginosa is significant respiratory tract
pathogen in community-acquired pneumonia (CAP) among patients with certain comorbidities and/or history of P. aeruginosa colonization or infection [3,8,9].
The greatest challenges with P. aeruginosa infections include its virulence and its intrinsic, acquired, and adaptive mechanisms of antibiotic resistance, often expressed
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simultaneously; which, have made infections caused by this pathogen particularly difficult to treat [4,10]. The frequency of multi-drug resistant (MDR) strains is increasing, and
MDR P. aeruginosa has been recognized by the Centers for Disease Control and Prevention
(CDC) as a serious public health threat [11–13]. Between 17% and 39% of P. aeruginosa
VABP isolates are MDR in the US [4]. MDR P. aeruginosa nosocomial pneumonia is associated with increased morbidity, mortality, length of hospital and intensive care unit stay,
and increased health care costs, likely related to inappropriate empiric therapy [14–20].
Existing treatment guidelines for P. aeruginosa include the 2019 Infectious Diseases
Society of America (IDSA) and American Thoracic Society (ATS) CAP guidelines and
newer treatment guidelines from IDSA for resistant Gram-negative infections [3,8,21,22].
However, treatment of P. aeruginosa pneumonia can vary based on patient-specific factors,
such as antibiotic allergies, drug toxicities and interactions, comorbidities, and the substantial heterogeneity of possible resistance mechanisms at play with P. aeruginosa. While
there is frequent discussion surrounding heterogeneity of patients and heterogeneity of
treatment effects, there is very little work evaluating differences in how patients are
treated (treatment heterogeneity). We do not have a good understanding of how patients
are treated beyond a single hospital or clinic. Furthermore, definitions of treatment in research tend to be overly simplistic and broad, leading to substantial misclassification of
treatment definitions. Therefore, real-world evidence must be interpreted with caution.
Over the past several years, our group has been studying treatment heterogeneity in serious bacterial infections, defined as drug-resistant infections requiring hospitalization and
associated with high mortality such as pneumonia and/or bloodstream infections [23]. We
have found that even in the presence of clinical guidelines, society guidelines, and/or hospital protocols to guide treatment for the optimal management of serious bacterial infections, substantial heterogeneity exists. We therefore wanted to assess whether heterogeneity persists in infections where there is limited evidence to support treatment guidelines, specifically P. aeruginosa pneumonia.
2. Results
2.1. Study Population
Our study included 5300 hospitalized patients from 112 hospitals in the national Veterans Affairs (VA) Healthcare system, with a P. aeruginosa isolated from respiratory tract
cultures collected between January 2015 and April 2018. Our study population was mostly
male (n = 5167, 97.5%), older (mean age 70.4 years, standard deviation [SD] 10.3; Table 1),
and White (n = 3956, 74.6%). About one-third (n = 1800, 34.0%) of patients received care in
intensive care units (ICU), and the comorbidity burden was high (median Charlson 3, interquartile range [IQR] 2–5; median Elixhauser 5, IQR 3–7]). Multidrug-resistant P. aeruginosa respiratory isolates were present in 12.4% (n = 636/5117) patients, with 22.0% (n =
1136/5157) demonstrating fluoroquinolone resistance and 19.0% (n = 874/4601) demonstrating carbapenem resistance. The median time from admission to P. aeruginosa culture
was 2 days (IQR 0–7).
Table 1. Demographics and comorbidities among patients with Pseudomonas aeruginosa pneumonia.

Demographics
Age (years), mean (SD)
Sex
Male
Female
Race
White
Black or African American
Asian

Total N = 5300
70.4 (10.3)
5167 (97.5%)
133 (2.5%)
3956 (74.6%)
1001 (18.9%)
24 (0.5%)
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Other
Unknown or decline to answer
Ethnicity
Hispanic
Not Hispanic or Latino
Unknown or decline to answer
Admission source
Home/community
Long-term care
Another hospital
Other/unknown
Intensive care unit during current admission
Surgery during current admission
Healthcare exposures, past 3 months
Hospitalization
Nursing home
Intensive care
Surgery
Multi-drug resistant isolate 1
Isolate resistance 2
Aminoglycosides
Carbapenems
Extended-spectrum cephalosporin
Fluoroquinolones
Piperacillin
Previous pseudomonas infection one year prior to admission
Charlson score 3
Median (interquartile range)
Elixhauser score 3
Median (interquartile range)
Cerebrovascular disease
Chronic pulmonary disease
Congestive heart failure
Diabetes without chronic complications
Diabetes with chronic complications
Dementia
Hemiplegia or paraplegia
Influenza
Malignancy
Mild liver disease
Myocardial infarction
Peripheral vascular disease
Renal disease
Tuberculosis

81 (1.5%)
238 (4.5%)
370 (7.0%)
4756 (89.7%)
174 (3.3%)
4721 (89.1%)
280 (5.3%)
155 (2.9%)
144 (2.7%)
1800 (34.0%)
942 (17.8%)
1968 (37.1%)
221 (4.2%)
356 (6.7%)
519 (9.8%)
636/5117 (12.4%)
691/5292 (13.1%)
874/4601 (19.0%)
887/5163 (17.2%)
1136/5157 (22.0%)
763/5000 (15.3%)
477 (9.0%)
3 (2–5)
5 (3–7)
686 (12.9%)
3648 (68.8%)
1838 (34.7%)
1493 (28.2%)
922 (17.4%)
379 (7.2%)
434 (8.2%)
122 (2.3%)
1288 (24.3%)
374 (7.1%)
586 (11.1%)
759 (14.3%)
1405 (26.5%)
51 (1.0%)

N (%), unless otherwise noted. 1 Multi-drug resistant isolate defined as any isolate that tested either intermediate or resistant to at least one antibiotic in at least three of the following categories:
aminoglyco-sides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, piperacillin/tazobactam. 2 Aminoglycosides (amikacin, gentamicin, tobramycin), carbapenems (imipenem,
meropenem, doripenem), extended-spectrum cephalosporins (cefepime, ceftazidime), fluoroquinolones (ciprofloxacin, levofloxacin), and piperacillin/tazobactam. Denominator changes for each
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antimicrobial category based on whether the isolate was tested for susceptibility to an antibiotic in
that category. 3 Calculated based on diagnosis during the current hospital admission.

2.2. Treatment Heterogeneity
When evaluating all antibiotics, 87.5% (n = 4635) of patients with P. aeruginosa pneumonia had unique antibiotic treatments, in terms of the specific antibiotic, timing of receipt of each antibiotic (which day of admission), and duration of therapy (Table 2). Most
(n = 4473, 84.4%) patients had a change in therapy, with a median of three changes over
the course of the hospitalization. Most changes (43.5%) were made the day after culture
collection, with a median time to first change of 1 day (IQR 0–2), median time to second
change of 2 days (IQR 1–4), and median time to third change of 4 days (2–6). Figure 1
demonstrates the 50 most common unique antibiotic treatment patterns (patterns alone
without duration of therapy), including changes in therapy, over the course of the admission [24].
Table 2. Treatment heterogeneity in patients with Pseudomonas aeruginosa pneumonia.

Treatment Patterns

No change in therapy

Change in therapy

Unique change patterns with
length of therapy, n (%)
Unique change patterns without length of therapy, n (%)
Number with change,
n (%)
Day of change from
culture, median (IQR)
Number of changes,
median (IQR)
Unique change patterns with length of
therapy, n (%)
Unique change patterns without length
of therapy, n (%)
Number without
change, n (%)
Unique non-change
patterns with length
of therapy, n (%)
Unique non-change
patterns without
length of therapy, n
(%)

Any Initial Antibiotic(s), then at Any Initial Antibiotic(s), then
All Antibiotics least One Anti-Pseudomonal An- only Anti-Pseudomonal Anti- Anti-Pseudomonal Antibiotic
Classes 3 (n = 4542/5300, 85.7%)
(n = 5300)
biotics 2
tibiotic 1
(n = 3530/5300, 66.6%)
(n = 576/3530, 16.3%)
4635 (87.5%)

3430 (97.2%)

527 (91.5%)

2294 (50.5%)

4004 (75.5%)

3049 (86.4%)

339 (58.9%)

1048 (23.1%)

4473 (84.4%)

3530 (100%)

576 (100%)

2640
(58.1%)

1 (0–2)

1 (0–2)

2 (1–3)

3 (1–4)

3 (2–5)

3 (2–5)

1 (1–2)

2 (1–3)

4331 (96.8%)

3430 (97.2%)

527 (91.5%)

2141
(81.1%)

3889 (86.9%)

3049 (86.4%)

339 (58.9%)

1027
(38.9%)

827 (15.6%)

-

-

1902
(41.9%)

304 (36.8%)

-

-

153 (8.0%)

115 (13.9%)

-

-

21 (1.1%)

IQR = interquartile range. Exposure mapping identified all antibiotics received each day, from three
days prior to the culture collection date until discharge, or 30 days from culture for longer hospital
stays. 1 Subgroup of first column, any initial antibiotic/s, then at least one anti-pseudomonal antibiotic. 2 Subgroup of second column, any initial antibiotic/s, then only anti-pseudomonal antibiotics.
3 Subgroup of first column, only anti-pseudomonal antibiotic classes assessed, may have received
other antibiotics. Anti-pseudomonal antibiotic classes included aminoglycosides (amikacin, gentamicin, tobramycin), carbapenems (imipenem, meropenem, doripenem), extended-spectrum cephalosporins (cefepime, ceftazidime), fluoroquinolones (ciprofloxacin, levofloxacin), piperacillin/tazobactam, polymyxins (colistin, polymyxin B), aztreonam, ceftazidime/avibactam, ceftolozane/tazobactam.
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Figure 1. Common treatment patterns. Alluvial chart demonstrates the 50 most common unique
antibiotic treatment patterns (patterns alone without duration of therapy) observed among all
patients (n = 5300), including changes in treatment, from three days prior to the culture collection
date until discharge, or 30 days from culture for longer hospital stays. The width of each line represents the number of patients receiving that specific treatment. Patients without changes in treatment are depicted in each segment as having the same antibiotic as the previous segment, while
those with changes, move to another antibiotic in the next segment. Different colors represent different antibiotics or concomitant antibiotics.

Among patients with any initial antibiotic therapy (monotherapy or combination
therapy), and changing to at least one anti-pseudomonal antibiotic (n = 3530, 66.6%), heterogeneity was higher at 97.2% (n = 3430/3530), with a median of three changes. Among
patients initially treated with any antibiotic and then changing to only anti-pseudomonal
antibiotics (n = 576, 10.9%), heterogeneity was 91.5% (n = 527/576). When assessing antipseudomonal antibiotic classes only, irrespective of other antibiotics received (n = 4542,
85.7%), heterogeneity was 50.5% (n = 2294/4542) and among those with changes in therapy, there were a median of 2 changes, with the first change most commonly occurring 3
days after culture.
The most commonly utilized antibiotics (Figure 2) [24] were vancomycin (n = 3106,
58.6%), piperacillin/tazobactam (n = 2563, 48.4%), levofloxacin (n = 1766, 33.3%), cefepime
(n = 1475, 27.8%), azithromycin (n = 1447, 27.3%), ceftriaxone (n = 1259, 23.8%), ciprofloxacin (n = 931, 17.6%), meropenem (n = 876, 16.5%), and metronidazole (n = 809, 15.3%).
Most patients (88.9%) were treated more than one antibiotic over the course of the admission (median antibiotics received 3, IQR 2–5). The utilization distribution of anti-pseudomonal antibiotic classes was 47.4% (n = 2510) for fluoroquinolones, 31.9% (n = 1692) for
extended-spectrum cephalosporins, 19.7% (n = 1045) for carbapenems, 8.3% (n = 440) for
aminoglycosides.
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Figure 2. Utilization of specific antibiotics. Antibiotic exposures were assessed from three days
prior to Pseudomonas aeruginosa culture collection date until discharge, or 30 days from culture
for longer hospital stays among all patients (n = 5300). Counts and percentages are not mutually
exclusive as 88.9% patients received more than one antibiotic over the course of the admission
(median number of antibiotics received 3, interquartile range 2–5). Different colors represent different antibiotics. Other antibiotics not included in the figure were used in <2% of patients.

When assessing anti-pseudomonal antibiotic classes only (n = 4542, 85.7%), irrespective of other antibiotics received and without considering duration of each antibiotic, only
eight patterns were observed in more than 2% of patients: (1) piperacillin/tazobactam
(15.8%), (2) fluoroquinolone (13.3%), (3) extended-spectrum cephalosporin (8.0%), (4) initial treatment with piperacillin/tazobactam alone, then a change to combination therapy
of a fluoroquinolone and piperacillin/tazobactam, and then a change to a fluoroquinolone
alone (discontinuation of piperacillin/tazobactam) (4.8%), (5) initial treatment with piperacillin/tazobactam alone, then a change to combination therapy of a fluoroquinolone and
piperacillin/tazobactam (2.9%), (6) initial treatment with an extended-spectrum cephalosporin, then a change to combination therapy of a fluoroquinolone and an extended-spectrum cephalosporin, and then a change to a fluoroquinolone alone (discontinuation of extended-spectrum cephalosporin) (2.4%), (7) carbapenem (2.3%), and (8) initial treatment
with piperacillin/tazobactam, then a change to combination therapy of an extended-
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spectrum cephalosporin and piperacillin/tazobactam, and then a change to an extendedspectrum cephalosporin alone (discontinuation of piperacillin/tazobactam) (2.1%).
2.3. Clinical Outcomes
Most patients had changes in therapy (n = 4473, 84.4%). Length of hospital stay, mortality, and persistent positive cultures were significantly higher among those who had
changes in therapy (Table 3, median length of stay admission to discharge 12 versus 4
days, inpatient mortality 17.1% versus 10.3%, persistent positive culture 38.1% versus
9.2%) as compared to those without changes in therapy. Among those without changes in
therapy (n = 827), length of stay and mortality were significantly lower among those
treated with monotherapy (n = 591, 71.5%) (median length of stay admission to discharge
5 versus 3 days, inpatient mortality 21.2% versus 5.9%) as compared to those treated with
combination therapy.
Table 3. Clinical outcomes in patients with Pseudomonas aeruginosa pneumonia.
Outcomes
Length of stay (days), admission to discharge, median
(IQR)
Length of stay (days), culture
to discharge, median (IQR)
Inpatient mortality, n (%)
Mortality within 30 days of
culture 1, n (%)
Readmission within 30 days
of discharge, n/n (%)
Persistent positive P. aeruginosa culture 2, n/n (%)
P. aeruginosa reinfection
within 30 days of discharge,
n/n (%)

No Change, No Change, CombinaChange in Therapy No Change in
p-Value Monotherapy
tion Therapy
p-Value
(n = 4473)
Therapy (n = 827)
(n = 591)
(n = 236)
12 (5–30)

4 (2–12)

<0.0001

5 (2–14)

3 (2–8)

<0.0001

8 (4–19)

2 (1–6)

<0.0001

3 (1–7)

2 (1–4)

<0.0001

765 (17.1%)

85 (10.3%)

<0.0001

35 (5.9%)

50 (21.2%)

<0.0001

891 (19.9%)

138 (16.7%)

0.03

67 (11.3%)

71 (30.1%)

<0.0001

121/556
(21.8%)
12/120
(10.0%)

34/186
(18.3%)
2/33
(6.1%)

30/556
(5.4%)

10/186
(5.4%)

808/3708 (21.8%)
679/1781 (38.1%)
244/3708 (6.6%)

155/742
(20.9%)
14/153
(9.2%)
40/742
(5.4%)

0.58
<0.0001
0.23

0.31
0.73 3
0.99

IQR = interquartile range. Percentages compared with Chi-square test, medians compared with
Wilcoxon test, unless otherwise indicated. 1 Inpatient or outpatient mortality. 2 Positive culture for
Pseudomonas aeruginosa after 7 days of treatment. Denominator only includes patients with followup cultures. 3 Fisher’s exact test.

3. Discussion
Among hospitalized patients with positive P. aeruginosa respiratory cultures, 87.5%
had different antibiotic treatment patterns, in terms of all antibiotics received each day
and the duration of each antibiotic therapy. This heterogeneity was largely driven by differences in antibiotic treatment patterns as opposed to duration of therapy (75.5% heterogeneity when not considering length of therapy versus 87.5% heterogeneity when including length of therapy). Treatment heterogeneity remained high, at approximately 50%,
even when restricting the analysis to anti-pseudomonal antibiotic classes only (not accounting for other antibiotics received) and duration of therapy, with duration accounting
for approximately half of the heterogeneity observed (heterogeneity of 23.1% when not
considering length of therapy). Most changes were made the day after culture collection,
which was likely when preliminary culture results were communicated to the treating
clinicians. Current methods to assess treatment, including intent-to-treat, as-treated, and
even time-dependent exposures, do not adequately account for the extensive heterogeneity observed in the treatment of infectious diseases. This misclassification has important
implications as clinical outcomes may vary between heterogeneous treatment approaches,
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which makes it difficult to attribute outcomes to one specific treatment approach. Future
work should investigate the impact of specific treatment approaches on clinical outcomes
in patients with P. aeruginosa pneumonia.
Inpatient mortality was highest among those initially receiving combination therapy
and continuing with that same combination therapy (no changes in therapy), and lowest
among those receiving only monotherapy (no changes in therapy). While this could indicate that initial targeted anti-pseudomonal monotherapy (monotherapy not requiring
changes in therapy) may be associated with better clinical outcomes, these patients may
have also been less complex, with less severe infections. It is also possible that since patients exposed to combination therapy were exposed to more antibiotics, they had a higher
risk for toxicity and adverse drug events than those exposed to monotherapy. As such,
these differences in outcomes require further study.
We observed higher rates of mortality in our study compared to the 8% mortality rate
reported by the CDC in 2019 for MDR P. aeruginosa infections, which included both respiratory and non-respiratory infections [13]. As worse outcomes, including mortality,
have been associated with MDR P. aeruginosa infections, and only 12.4% of our population
had MDR P. aeruginosa, the clinical significance of pneumonias caused by all P. aeruginosa,
including both MDR and susceptible strains, cannot be understated [25–29].
Empiric treatment recommendations for P. aeruginosa pneumonia endorsed by the
IDSA include piperacillin-tazobactam (4.5 g every 6 h), cefepime (2 g every 8 h),
ceftazidime (2 g every 8 h), imipenem (500 mg every 6 h), meropenem (1 g every 8 h), or
aztreonam (2 g every 8 h) [3,8]. Newer treatment guidelines from IDSA for resistant Gramnegative infections recommend monotherapy with ceftolozane-tazobactam, ceftazidimeavibactam, or imipenem-cilastatin-relebactam for infections outside the urinary tract
caused by difficult to treat (DTR) P. aeruginosa (defined as non-susceptibility to all of the
following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem,
imipenem-cilastatin, ciprofloxacin, and levofloxacin) [21,22]. If none of these newer betalactam/beta-lactamase inhibitors are options due to intolerance or resistance, alternative
treatment options include cefiderocol or an aminoglycoside, such as plazomicin [21].
However, it should be noted there is limited clinical data supporting treatment recommendations of DTR P. aeruginosa and older treatment options, such as aminoglycosides
and colistin, are recognized to have significant toxicity issues [21].
While existing guidelines address empiric treatment options for P. aeruginosa pneumonias, given the complexity and variability of antibiotic resistance patterns among P.
aeruginosa strains causing infection, guidelines may benefit from specific and tailored recommendations. For example, the use of guideline-recommended empiric therapy for
highly resistant P. aeruginosa strains could lead to initial treatment failure, while empiric
therapy may be excessively broad for more sensitive P. aeruginosa strains, which could
lead to longer hospital stays, and increased risk of developing additional resistance or
Clostridioides difficile infections [30–33].
The fundamental principle in treatment of serious P. aeruginosa infections is early administration of appropriate antibiotics [34]. Previous work has demonstrated that the
odds of mortality in patients with P. aeruginosa pneumonia is up to 3 times higher in those
treated with inappropriate versus appropriate empiric treatment [35,36]. As such, best
practice guidelines for community-acquired and HABP/VABP both recommend empiric
treatment with conventional anti-pseudomonal β-lactams (meropenem, imipenem, doripenem, piperacillin-tazobactam, cefepime, and ceftazidime), potentially in combination
with a second agent (aminoglycoside, fluoroquinolone, or polymyxin), when P. aeruginosa
is suspected [8,34,37]. Two agents are generally recommended until bacterial susceptibly
results are available, if the patient has specific risk factors for MDR P. aeruginosa, such as
high risk for mortality, previous intravenous anti-pseudomonal antibiotic therapy, and/or
based on local susceptibility data [8,34,37–39]. These recommendations are centered
around the goals of achieving early appropriate therapy while also limiting superfluous
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coverage, which increases the risk of adverse drug effects, Clostridioides difficile infections,
and antimicrobial resistance [37].
Use of newer β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, cefiderocol, and imipenem-cilastatin-relebactam, may also be considered for
treatment of P. aeruginosa pneumonias. Empiric or targeted use of newer agents may increase earlier receipt of appropriate therapy, particularly for resistant P. aeruginosa infections, while decreasing the risk of unintended effects from combination therapy with
older, more toxic antibiotics [40,41]. However, their role in therapy has yet to be fully elucidated and these agents remain largely absent from guidelines [34]. For directed therapy,
while it has been postulated that continued combination therapy may minimize the emergence of resistance and promote antimicrobial synergy, there is a lack of data to support
these hypotheses [42,43]. As such, once culture results are available, it is generally recommended to streamline treatment to a single, highly active agent for the directed treatment
of P. aeruginosa pneumonia [34]. Despite these general recommendations, there is a lack of
high-level evidence to firmly guide treatment decisions, especially for patients with infections due to resistant phenotypes, in part, because it is not a requirement for the approval
of new antibiotics [44].
Treatment patterns observed in our study were consistent with best practice guidelines for the treatment of CAP and HABP/VABP guidelines [3,8,9,21,37]. It is generally
recommended that a β-lactam plus a macrolide or a respiratory fluroquinolone are used
for empiric treatment of CAP in hospitalized patients without suspicion for P. aeruginosa,
which is consistent with our findings regarding the frequency of use of ceftriaxone
(23.8%), azithromycin (27.3%), and levofloxacin (33.3%). For HABP/VABP, piperacillin/tazobactam or cefepime are generally recommended for empiric treatment, with the
addition of vancomycin if there are risk factors for methicillin-resistant Staphylococcus aureus (MRSA) or the local prevalence of MRSA is high (>20%) [8]. While P. aeruginosa is
intrinsically resistant to ceftriaxone, azithromycin, and vancomycin, these represent recommended empiric treatment options for CAP (ceftriaxone and azithromycin) [8] and
MRSA (vancomycin) [37], and do not preclude their use for the treatment of concomitant
infections or syndromes, such as chronic obstructive pulmonary disease or another infection type. For directed anti-pseudomonal therapy, single-agent conventional therapy
(piperacillin-tazobactam, cefepime, and ceftazidime) based on susceptibilities is generally
recommended, with carbapenems (meropenem, imipenem, doripenem) potentially being
reserved for more resistant phenotypes or polymicrobial infections [8,37].
Real-world data evaluating P. aeruginosa pneumonia treatments are limited. A recent,
observational cohort study compared ceftolozane/tazobactam to polymyxin or aminoglycoside-based regimens for the treatment of resistant P. aeruginosa infections (52% VABP)
[45]. This study similarly demonstrated the frequent use of conventional anti-pseudomonal therapy in the polymyxin or aminoglycoside-based combination treatment group
with carbapenems, piperacillin/tazobactam, and extended-spectrum cephalosporins most
commonly being used. However, detailed descriptions of treatment patterns were not described, nor were additional agents used for any polymicrobial infections or concomitant
infections.
Resistance rates in our cohort were lower than previous reports, with 12.4% demonstrating MDR, 13.1% with aminoglycoside resistance, 19.0% with carbapenem resistance,
17.2% with extended-spectrum cephalosporin resistance, 22.0% with fluoroquinolone resistance, and 15.3% with piperacillin resistance. Alternatively, of 1412 P. aeruginosa isolates
from adult patients with VAP submitted to the National Healthcare Safety Network
(NHSN) between 2015–2017, between 17 and 39% were MDR, dependent on hospital location [4]. In the NHSN, reported rates of resistance in VABP P. aeruginosa were generally
higher than rates observed in our study (aminoglycosides 13.6–29.9%, carbapenems 26.3–
61.4%, extended-spectrum cephalosporin 25.9–44.7%, fluoroquinolones 26.7–45.8%, and
piperacillin/tazobactam 21.7–34.8%) [4]. Rates of resistance may have been lower if the
NHSN data included isolates from CAP. Similarly, of 258 patients with P. aeruginosa
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nosocomial pneumonia from 3 hospitals in the US, 20.5% were MDR, and reported resistance rates for each class of antibiotics were higher than those we observed (aminoglycosides 19.2%, carbapenems 21%, extended-spectrum cephalosporin 18.6%, fluoroquinolones 24.1%, and piperacillin/tazobactam 17.4%) [14]. Twenty-years of surveillance data
(1997–2016) from the worldwide SENTRY Antimicrobial Surveillance Program also
demonstrated higher rates of resistance than we observed in our cohort [46]. The overall
rate of MDR clinical P. aeruginosa isolates was 24.9%, with the highest rates among those
with pneumonia (27.7%) [46]. Isolates with MDR phenotypes were less common in North
America (18.9%) than other regions worldwide, but still higher than the rate we observed.
Despite general recommendations, there are limited comparative data to support the
most optimal agent/s to use for treatment of P. aeruginosa pneumonia, especially those due
to resistant phenotypes. More comparative clinical data is needed to identify if there are
preferred antibiotic agents overall for P. aeruginosa pneumonia or if there are clinical scenarios in which certain agents may be preferred [34,42]. Additionally, more data is needed
to identify when combination therapy may be most beneficial to patients with P. aeruginosa pneumonia and what antibiotic combinations are associated with the highest effectiveness and safety. Additional data may also be important to determine if there is a need
to tailor antibiotic regimens based on the risk or presence of MDR isolates. These gaps in
knowledge need to be filled with strong real-world clinical data for guidelines and hospital protocols to outline optimal therapy for patients with serious P. aeruginosa infections.
The high treatment heterogeneity we observed, even despite clinicians commonly using
recommended agents, highlights the continued uncertainty surrounding optimal treatment of P. aeruginosa infections and the need for clearer, more detailed evidence-based
specific treatment guidelines based on patient risk factors and/or local epidemiology.
There are limitations to this retrospective observational study. We were unable to
distinguish between true infection versus colonization as clinical signs and symptoms and
signs of pneumonia were not captured. However, 72% of patients had a pneumonia diagnosis during the admission. It is possible that the treatment captured may have been for
another infection or for a concomitant and/or polymicrobial infection. Furthermore, we
were also unable to classify the type of pneumonia (HABP/VABP/vHABP versus CAP)
diagnosed. Given the differential burden of pseudomonal HABP/VABP/vHABP and CAP
on mortality as identified in previous studies [17], stratification of these diagnoses could
help inform the clinical outcomes seen in our cohort. The reasons for changes in antibiotic
therapy are unknown. We measured the time from culture collection to antibiotic change
as opposed to time from culture results, including pathogen identification and antimicrobial susceptibilities. Potential reasons for change include possible antibiotic de-escalation
or escalation based on pathogen and/or susceptibly results, clinical improvement or worsening of clinical signs and symptoms, or care transitions (such a preparatory to discharge,
discontinue intravenous antibiotics for oral).
Our estimate of heterogeneity is likely an underestimate, as it did not include changes
in route (for example, intravenous to oral changes) or dose, antibiotics received in other
non-VA settings (non-VA nursing home or non-VA hospital), inhaled antibiotics, or postdischarge antibiotics. Similarly, outcomes were only captured among those who were
treated in VA facilities and not those who sought treatment outside the VA. Susceptibility
testing across the VA Healthcare system is not uniform which may lead to inconsistencies
in determining antibiotic resistance and MDR. However, accepted definitions of the CDC
NHSN were used to identify MDR phenotypes [47]. While several demographics and clinical characteristics of the study cohort were described, previous antibiotic exposures, one
of the main risk factors for resistant pseudomonal infections, were not assessed. The generalizability of this study is limited to patients admitted to VA hospitals. Heterogeneity
among VA hospitals may be lower than other non-VA hospitals, as the VA is the nation’s
largest integrated healthcare system and while there are no national VA guidelines for
treatment of P. aeruginosa pneumonia, resources and education are often shared among
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local VA facilities through national antibiotic stewardship resources and initiatives, such
as the national VA Antibiotic Stewardship Task Force.
4. Materials and Methods
4.1. Study Population
Our study included hospitalized patients >18 years old with P. aeruginosa isolated
from respiratory tract cultures (sputum and/or bronchoalveolar lavage) collected between
January 2015 and April 2018 in the national VA Healthcare System. The culture could be
collected anytime during admission and only the first hospitalization identified during
the study period was selected for inclusion. This study was approved by the Institutional
Review Board and Research and Development Committee of the VA Providence
Healthcare System.
4.2. Exposure Mapping
We utilized exposure mapping to identify all antibiotics received on each day, from
three days prior to the culture collection date until discharge, or 30 days from culture for
longer hospital stays. With exposure mapping, all antibiotic exposures are captured,
which allows assessment of combination therapy, duration of therapy, and changes in
therapy. Antibiotic exposures were captured from barcode medication administration records and pharmacy dispensings, which include antibiotics given in the emergency department.
4.3. Treatment Heterogeneity
Measures of heterogeneity included number of changes in therapy and time to first
change for each patient. Time to first change was assessed to capture initial change from
empiric to targeted therapy after initial culture results are communicated to the treating
clinician. Treatment patterns were built from daily antibiotic exposures and duration of
each antibiotic exposure, and therefore captures all changes in antibiotic treatments day
to day. Dose changes and changes from intravenous to oral forms of the same antibiotic
were not considered changes in therapy. Exposure mapping was carried out for (1) all
antibiotics, (2) any initial antibiotic/s and then at least one anti-pseudomonal antibiotic at
the first change in therapy (aminoglycosides: amikacin, gentamicin, tobramycin; carbapenems: imipenem, meropenem, doripenem; extended-spectrum cephalosporins:
cefepime, ceftazidime; fluoroquinolones: ciprofloxacin, levofloxacin; piperacillin/tazobactam; aztreonam; polymyxins: colistin, polymyxin B; ceftazidime/avibactam;
ceftolozane/tazobactam), (3) any initial antibiotic/s and then only anti-pseudomonal antibiotics after first change, and (4) only assessing anti-pseudomonal antibiotic classes.
The definition of a common, or shared, treatment pattern was at least two patients
hospitalized with positive P. aeruginosa respiratory tract cultures and treated with the
same antibiotic exposures for the same duration. Therefore, unique treatment patterns
were those where only a single patient had a specific treatment pattern, assessed either at
the antibiotic or as antibiotic class level and accounting for duration. Non-unique treatment patterns were defined as those where multiple admissions had the same pattern of
antibiotic exposures and durations. For example, the following was a treatment pattern
shared by several patients: piperacillin/tazobactam plus vancomycin for three days, which
was changed to only piperacillin/tazobactam for five days. In contrast, this was an example of a unique treatment pattern which was only identified in one patient: amoxicillin/clavulanate for one day, which was changed to piperacillin/tazobactam for six days
and then changed to levofloxacin and piperacillin/tazobactam for one day.
4.4. Clinical Outcomes
Outcomes assessed included length of stay (from admission and culture collection to
discharge), mortality (inpatient and 30-day from culture), readmission within 30 days of
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discharge, persistent positive P. aeruginosa culture, and P. aeruginosa reinfection within 30
days of discharge. Persistent positive P. aeruginosa culture was defined as a positive sputum and/or bronchoalveolar lavage for P. aeruginosa after 7 days of treatment. P. aeruginosa
reinfection was defined as a positive sputum and/or bronchoalveolar lavage culture for P.
aeruginosa after discharge.
4.5. Statistical Analysis
Outcomes were compared between patients who had changes in therapy and no
changes in therapy, and among those who had no changes in therapy, between those
treated with monotherapy and combination therapy. Proportions of categorical variables
were compared between groups using Chi-square tests (one comparison with expected
cell count <5 utilized Fisher’s exact test, as indicted in Table 3) and the non-parametric
Wilcoxon test when comparing medians of continuous variables. Statistical significance
was considered at a p-value < 0.05. Analyses were completed with SAS (Version 9.2; SAS
Institute, Inc.: Cary, NC, USA).
5. Conclusions
In our retrospective cohort study of 5300 MDR P. aeruginosa infections, treatment heterogeneity was high, ranging from 97.2% in patients receiving any initial antibiotic/s with
a change to at least one anti-pseudomonal antibiotic, to 50.5% when assessing anti-pseudomonal antibiotic classes, irrespective of other antibiotic received. Real-world evidence
is needed to help support and inform the development of treatment protocols and antibiotic stewardship programs based on clinical and patient outcome data, which is currently
lacking in the presence of such treatment heterogeneity.
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